- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
1. Financial Highlights:
Alembic Pharmaceuticals posted Q4 revenue of INR 1,770 Cr, up 17% YoY and 5% QoQ. EBIDTA stood at INR 286 Cr with a margin of 16.15%, while net profit was INR 157 Cr, translating to an 8.9% margin. Full-year revenue grew 7.1% to INR 6,672 Cr. India branded formulations grew 8% YoY to INR 545 Cr in Q4. US generics surged 20% YoY to INR 508 Cr, supported by new launches. Ex-US generics rebounded strongly with 43% growth. API revenues were stable, rising 4% YoY. R&D spend remained robust at 9% of sales, backing an active innovation pipeline.
2. Strategic Initiatives & Growth Drivers:
Alembic is driving digital sales transformation using iPad detailing and Salesforce CRM. The new Indore manufacturing plant commenced production, expanding capacity. US oral solids manufacturing is scaling, with 15+ product launches planned next year. Rest of World markets are growing via new filings and entry into Chile. India’s portfolio is bolstered by prescription launches in gynecology, anti-diabetic, and gastro segments. AI-powered tools like a GenAI WhatsApp bot are enhancing internal productivity.
3. Business Developments:
Four new US product launches and five ANDA filings in the quarter (24 approvals YTD) demonstrate steady pipeline progression. Ex-US business expanded through partnerships and new footprints in Europe, Canada, Australia, Brazil, South Africa, and Chile. The animal health segment grew 19%, maintaining leadership in haematinics and antibiotics. API filed five DMFs in the US, supporting ongoing capacity expansions.
4. Market Position & Competitive Advantage:
Alembic holds a 1.4% share in the Indian pharma market, ranked 20th, with strength in specialty therapies. It markets 163 products in the US and has an export reach of API to 60+ countries. A large sales force of 5,500+ reps and focused therapeutic portfolios, enhanced by digital tools, support competitive differentiation. Strong sustainability practices and a zero-fatality workplace reinforce operational excellence.
5. Investor Implications:
Robust growth in US and ex-US generics alongside steady India branded expansion indicate positive growth potential. Capacity ramp-up and a deep R&D pipeline support scaling prospects. Digital sales transformation may boost efficiency. Execution risks around product launches and capacity build-out warrant monitoring, but current momentum across markets and verticals is encouraging.